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ABSTRACT
CD160 is a T cell coinhibitory molecule that interacts with the herpes virus entry 
mediator (HVEM) on antigen-presenting cells to provide an inhibitory signal to T cells. 
To date, the structure of CD160 and its complex with HVEM are unknown. Here, we 
have identified the fragments of CD160 interacting with HVEM using ELISA tests, 
hydrogen/deuterium studies, affinity chromatography and mass spectrometry (MS). 
By combining hydrogen/deuterium exchange and mass spectrometry (HDX-MS) we 
obtained key information about the tertiary structure of CD160, predicting the 3D 
structure of the CD160–HVEM complex. Our results provide insights into the molecular 
architecture of this complex, serving as a useful basis for designing inhibitors for 
future immunotherapies.
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INTRODUCTION
Among the most promising approaches to activate 
the immune system is the inhibition or stimulation of 
immune checkpoints. Cosignaling molecules have been 
implicated in the dysregulation of immune responses in 
autoimmunity, chronic infections, and cancers [1–3]. 
Numerous immune checkpoints (either coinhibitory or 
costimulatory) have been identified, which are candidate 
targets for immunotherapy: CTLA-4 and its ligands B7.1/
B7.2 [4, 5], PD-1 and PDL-1/PDL-2 [6, 7], TIGIT and 
CD155 [8], OX40 and OX40L [9], TIM-3 and Galectin-9 
[10], and the recently discovered BTLA and HVEM [11, 12] 
or CD160 and HVEM [13]. Most cosignaling molecules 
are members of the immunoglobulin superfamily (IgSF) 
or tumor necrosis factor superfamily (TNFSF). In general, 
the Ig superfamily receptors bind to the Ig superfamily 
ligands and TNF receptors superfamily (TNFRSF) bind 
to TNF ligands superfamily (TNFSF). Until now, the 
CD160–HVEM and BTLA–HVEM interactions are the 
only examples of signaling complexes between members 
of the two distinct families: IgSF and TNFRSF. 
Herpes virus entry mediator (HVEM) acts both as 
a ligand for the Ig superfamily proteins, BTLA [11, 12], 
and CD160 [13] and as a receptor for TNFSF ligands, 
LIGHT, and Lymphotoxin α (LTα) [14, 15]. Interaction 
of HVEM with CD160 and BTLA triggers a coinhibitory 
signal to T-cell activation, whereas its interaction with LTα 
and LIGHT leads to a costimulatory signal. Thus, HVEM 
could regulate the host immune response, and that process 
depends on the type of ligand of HVEM that is involved 
[16, 17].
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HVEM is a transmembrane protein, which has three 
full cysteine-rich domains (CRD), each of them stabilized 
by three disulfide bridges. The fourth CRD domain of 
HVEM contains only two of the three disulfide bonds 
[18–20]. The analysis of binding sites of HVEM showed 
that LIGHT and LTα interact with the CRD2 and CRD3 
domains of HVEM [21, 22], while BTLA [21] and CD160 
[13] bind to the CRD1 region.
In contrast to BTLA and HVEM [21], no crystal 
structure of the CD160–HVEM complex is available. 
The CRD1 domain of HVEM, crucial for the binding 
of coinhibitory molecules, interacts also with the 
glycoprotein D (gD) from the herpes simplex virus 
[23–25]. The interactions in the BTLA–HVEM and 
gD–HVEM complexes are very similar. Both proteins 
bind to HVEM using two short β-strand fragments, which 
form hydrogen bonds with β-strand presented in the CRD1 
domain of HVEM. Despite the similarity of the structure 
of these strands in BTLA and gD, a comparison of their 
sequences shows that they have no sequence identity 
and only have modest sequence similarity, indicating 
the dominant role of backbone hydrogen bonds in the 
intermolecular β-sheet of the complex formation [21, 26]. 
Some studies showed that HVEM probably interacts with 
CD160 in a similar way as BTLA and gD. CD160 binds to 
HVEM with a similar affinity, but at a slower dissociation 
rate than BTLA and competes with BTLA for binding to 
HVEM [27]. 
CD160 is a glycosylphosphatidylinositol-anchored 
membrane glycoprotein (CD160–GPI) with a single IgV-
like domain that belongs to the Ig superfamily. Three other 
isoforms of CD160 are also described (CD160DIg–GPI, 
CD160–TM, CD160DIg–TM), which are generated by 
alternative splicing. They differ from each other by the 
presence or absence of the Ig domain, the transmembrane 
domain, and/or the GPI motif [28, 29]. CD160–GPI and 
CD160–TM isoforms interact with HVEM, indicating 
that the Ig domain is necessary for the protein binding 
[28, 29]. Four different isoforms of CD160 have been 
identified, but only two of them (with IgV-like domain) 
can bind to HVEM [29, 30]. The extracellular domain of 
CD160 contains five cysteine residues, four of them form 
disulfide bridges (Cys18–Cys86 and Cys35–Cys42) and 
one in the position 87 has a free sulfhydryl group [28]. 
The protein also has two sites for N-linked glycosylation, 
and the asparagine in positions 2 and 111. CD160 also 
binds to MHC class I molecules with low affinity and this 
binding might enhance NK and T-cell cytolytic activity 
[30]. The function of CD160 has not yet been fully 
characterized beyond the finding that CD160 can decrease 
the proliferation and the cytokine production of CD4+ and 
CD8+ T-cells upon binding to HVEM [13, 29].
Herein, by combining in vitro and in silico analyses, 
we identified the binding sites of CD160 that are 
responsible for the interaction with HVEM. In addition, 
by performing a molecular docking of CD160 to HVEM, 
we generated a predictive model of the 3D structure of 
this complex.
RESULTS
H/D exchange pattern in the CD160 protein
To obtain the structural information about the 
CD160 protein, a HDX-MS experiment was performed. 
In this experiment proteins in aqueous buffer are diluted 
in D2O buffer, which results in replacement of proteins 
hydrogens with deuteria. The rate of exchange depends on 
chemical properties of amino acid residues, pH of buffer 
and temperature, but also on structural properties of the 
protein. Hydrogens involved in hydrogen bond formation 
do not until the H-bond is broken. High level of exchange 
characterizes unstructured, more dynamic regions of 
protein. Low levels of exchange are characteristic for 
rigid structures. Using mass spectrometry we can measure 
the mass difference resulting from hydrogen/deuterium 
exchange in different peptides derived from a protein 
after enzymatic fragmentation. It allows investigation of 
protein’s dynamics and dynamical changes occurring as a 
result of interaction with other proteins, ligands, lipids etc.
In Figure 1 red and orange regions indicate CD160 
protein exposed to solvent, blue and green regions are 
less susceptible to H/D exchange. Our results show that 
the H/D exchange in N-terminus of the CD160 protein 
(residues 1–15) is very fast (more than 70%), indicating 
a flexible structure in this region. A similar process was 
observed for the middle part of protein (position 35–65, 
76–83 and 89–97). Residues 17–21, 31–34, 71, 83–87, 
98–106 and 126–132 represent more structured regions 
(Figure 1). 
In addition, to obtain the maximal resolution of 
the HDX-MS experiment and sequence coverage, the 
CD160 protein was digested with two enzymes (protease 
type XIII from A. saitoi and pepsin). Digestion of protein 
generated 45 peptides, covering sequence in 80.9% with 
average redundancy 5.28 (Supplementary Figure 1). The 
enzymatic digestion of the CD160 protein generated only 
one peptide ((15 amino acids (aa)) from the N-terminus. 
On the other hand, many peptide fragments were 
found (6 to 32 aa) from the central part of the protein. 
The C-terminal fragments (residues from 107 to 124 
and from 133 to 141) of the CD160 protein were not 
detected in any of the performed MS experiments. The 
lack of C-terminal peptides and the presence of only 
one peptide from N-terminal part of the protein in digest 
mixture might be the result of glycosylation of Asn2 
and Asn111 residues. The presence of carbohydrates 
may create a hindrance in the enzymatic digestion and 
ionization of proteins [31]. Furthermore, ELISA test for 
CD160 and deglycosylated CD160 (obtained by using 
PNGase F enzyme) proteins were performed. Our results 
indicated that the deglycosylated CD160 protein has a 
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very low affinity to the HVEM protein. This suggests that 
deglycosylation changed the structure or/and activity of 
CD160 (Supplementary Figure 2).
Identification of sites that help binding of CD160 
to HVEM using HDX-MS
Measuring the level of H/D exchange for CD160–
HVEM complex and comparing the level of exchange in 
CD160 free protein indicates the regions, whose dynamics 
changed upon interaction. Figure 2 illustrates the regions 
that are more protected from exchange and had less 
H/D exchange upon protein binding are implicated in 
the interaction with HVEM. Deuteration was measured 
after incubating in deuterated PBS for 10s, 1 min, 5 min, 
25 min, and 2 h. Results show that significant decrease in 
the deuteration of CD160–HVEM complex, as compared to 
CD160 alone were observed in following peptides, namely: 
CD160(16–21), CD160(30–34), and CD160(76–87) 
(Figure 2). For H/D data presenting the exchange in the 
remaining regions and p-values calculated using Student’s 
t-test for peptides after n time of HD exchange see 
Supplementary Materials (Supplementary Figure 3 and 
Supplementary Table 1).
Identification of the CD160 binding sites to 
HVEM using affinity chromatography and 
ELISA tests
Next, we synthesized 10 long peptides (20–25 
(aa) long, overlapped by 8 aa) covering the Ig-V 
domain of CD160. In order to prevent the formation of 
inter- and intramolecular disulfide bridges, all cysteines 
were replaced by 2-aminobutyric acid (Abu), which 
is isosteric to cysteine. Then, peptides were analyzed 
in an affinity test using the microcolumn containing 
immobilized HVEM protein. Three fractions, the 
supernatant, last wash, and elutions were analyzed 
using mass spectrometry. In the supernatant fraction, 
the signal m/z corresponding to the unbound peptide 
was observed. In the last wash fraction, no signal was 
observed, which confirms that the excess of peptide was 
removed. The observation of m/z signal in the elution 
indicated that the complex between HVEM and CD160 
peptide was formed. Indeed, peptides CD160(13–32), 
CD160(25–44), CD160(61–80), CD160(73–92) and 
CD160(85–104) were bound to HVEM protein (Table 1). 
Fragment CD160(97–116) showed very bad solubility in 
all the tested solutions (H2O, DMF, DMSO, etc.) and thus 
Figure 1: HDX-MS heat map representing the pattern of exchange in CD160 protein.
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could not be analyzed using the affinity chromatography. 
Therefore, two additional, shorter fragments were 
synthetized and analyzed: CD160(97–110) and 
CD160(103–116) (see Table 1—marked with an asterisk 
(*)). The affinity test indicated that the peptide CD160(97–
110) interacts with HVEM protein. 
Then, in order to determine which of the above 
CD160 fragments has higher affinity to HVEM, an 
ELISA test was performed. For this purpose, CD160 
protein was biotinylated, whereas CD160 fragments were 
elongated by five glycine residue and biotin to attach it on 
a streptavidin-coated surface. In Figure 3 the absorbance 
for the HVEM-Fc in different concentrations (20, 10, 
and 5 µg/ml) is shown. The ELISA results show that the 
strongest affinity to the HVEM revealed CD160(13–32) 
peptide. We found that three fragments - CD160(25–44), 
CD160(61–80), and CD160(73–92) interact also with 
HVEM, but with a lower affinity. The other analyzed 
peptides show very weak or no affinity to HVEM. Based 
on these results it is possible to conclude that 13–44 and 
61–92 regions of CD160 can bind to HVEM protein. 
For the fragments CD160(85–104) and 
CD160(97–110) the very strong signals in ELISA assays 
were observed. As negative control, we have checked 
what will be the absorbance signal for all peptides in 
the ELISA test, but without the HVEM protein. In this 
test the high absorbance was detected only for those two 
peptides - CD160(85–104) and CD160(97–110). Many 
assay conditions, such as various microplates, buffers, 
blocking solutions, concentrations, and plate-wash steps 
were tested by us. In each tested trial, the absorbance 
signal from only CD160 (85–104) and CD160 (97–110) 
peptides was similarly high. In order to check sequence 
specificity, for both interacting peptides also the scrambled 
peptides were synthesized and studied. Obtained results 
for scrambled peptides were very similar to CD160(85–
104) and (97–110) peptides, what might suggest non-
specific interactions of these peptides with HVEM protein 
(see Supplementary Figure 4). 
Structure determination of the CD160 protein 
To obtain a reliable full-length structural model of 
CD160 protein, the I-TASSER homology modeling was 
established at the first step of the CD160 protein structure 
determination. The following protein structures from PDB, 
all sharing an immunoglobulin-like fold, were chosen by 
I-TASSER as templates in the modeling: 1TJH, 1Q8M, 
4WEB, 2AGJ, 2IQA, 7FAB, 1KB9 [32]. Best homology 
modeling structure was obtained with high C-score 
–2.65. In the I-TASSER program no sequences that were 
homologous for the C-terminal part of the CD160 protein 
were found. Therefore, C-terminus fragment (119–159) 
was calculated in a coarse-grained force field.
Next, the final I-TASSER model (with the highest 
C-score) together with C-terminus (119–159 fragments) 
was selected for the structure calculation in a coarse-
grained force field. To get folded structures of the CD160 
protein, the multiplexed replica exchange molecular 
dynamics (MREMD) was performed. Finally, we obtained 
20 structures (model I to XX, Supplementary Figures 5 
and 6) of the CD160 protein. From all the obtained 3D 
structures the best one (model XX), which matched the 
experimental criteria (HDX-MS results, disulfide bonds 
positions and IgV immunoglobulin fold), was chosen as 
the final structure. This structure was further used for the 
model validation process. 
The best 3D structure of the CD160 protein 
(Figure 4A) was then validated. The overall model 
quality (z-score) for the CD160 protein is –3.7 [33]. 
Figure 2: Regions of CD160 protein with important changes in deuteration level upon interaction with HVEM. CD160 
in complex with HVEM (blue line) and free CD160 (red line). Deuteration was measured after incubating in deuterated PBS for 10 s, 1 min, 
5 min, 25 min, and 2 h, which is shown on a logarithmic scale.
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This value indicates that this model is of good quality 
(see Supplementary Figure 7). The final structure 
of the CD160 protein is a typical β-sandwich Ig fold 
containing nine β-strands [34]. Similarly, to other Ig-
like proteins, it belongs to the IgV-like domain of the Ig 
superfamily and consists of two tightly packed β-sheets 
- one composed of 4 strands (1, 4, 5, and 9) and the other 
of 5 strands (2, 3, 6, 7, and 8), which are connected by 
nine loops (Figure 4) with one short α-helix between 
β4 and β5 strands. In the first and second β-sheets, all 
strands are arranged in an antiparallel fashion. From our 
experimental studies, it is possible to define that in the 
final structure the β2 (residues 17–28) and β3 (residues 
29–37) strands and the loop between the β5 and β6 
strands (residues 74–82) together form the binding site 
for HVEM protein.
Figure 3: ELISA test results for the binding of CD160 protein and its fragments to HVEM-Fc protein. Statistical analysis 
was performed by comparing each concentration of HVEM-Fc to the same concentration in the PBS condition.***p < 0.001, **p < 0.01, 
*p < 0.05.
Table 1: Microcolumn affinity tests
Peptide Sequence [M+H]+calc.
Supernatant 
[M+H]+
Last 
wash 
Elution 
[M+H]+
CD160 (1–20) INITSSASQEGTRLNLIAbuTV-NH2 2101.36 2101.02 n.o. n.o.
CD160 (13–32) Ac-RLNLIAbuTVWHKKEEAEGFVV-NH2 2394.77 2394.37 n.o. 2394.32
CD160 (25–44) Ac-EEAEGFVVFLAbuKDRSGDAbuSP-NH2 2193.37 2193.21 n.o. 2193.19
CD160 (37–56) Ac-DRSGDAbuSPETSLKQLRLKRD-NH2 2327.56 2327.17 n.o. n.o.
CD160 (49–68) Ac-KQLRLKRDPGIDGVGEISSQ-NH2 2237.52 2237.10 n.o. n.o.
CD160 (61–80) Ac-GVGEISSQLMFTISQVTPLH-NH2 2185.50 2185.13 n.o. 2185.23
CD160 (73–92) Ac-ISQVTPLHSGTYQAbuAbuARSQK-NH2 2212.47 2210.11 n.o. 2210.19
CD160 (85–104) Ac-QAbuAbuARSQKSGIRLQGHFFSI-NH2 2271.58 2271.43 n.o. 2271.15
CD160 (97–116) Ac-LQGHFFSILFTETGNYTVTG-NH2 2273.50 - - -
*CD160(97-110) Ac-LQGHFFSILFTETG-NH2 1637.83 1637.65 n.o. 1637.65
*CD160(103-116) Ac-SILFTETGNYTVTG-NH2 1543.67
1565.60 
[M+Na]+ n.o. n.o.
CD160(109-133) Ac-TGNYTVTGLKQRQHLEFSHNEGTLS-NH2 2859.07 2859.23 n.o. n.o.
n.o. – not observed; - – not results.
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The CD160–HVEM complex model 
We next formed the CD160–HVEM complex 
model. The predicted CD160 protein was docked to 
the crystal structure of HVEM (PDB code: 2AW2). 
Validation of UNRES docking method with use of 
BTLA-HVEM complex was performed, starting from 
random orientation of both proteins with respect to 
each other. UNRES docking was able to find correct 
(as in crystal structure) protein orientation with an 
average RMSD of the third cluster of 1.68 Å (see 
Supplementary Figure 8). The CD160–HVEM complex 
structure, obtained from clustering after the UNRES 
simulation, with the highest probability (the lowest free 
energy) is shown in Figure 5. In the HVEM (orange) - 
CD160 (light blue) complex the interacting fragments 
are colored in red and dark blue, respectively. The 
CD160 binds to HVEM by large β-sheet surface. 
When the contact map (colored in grayscale) between 
two proteins in this theoretical complex was analyzed 
(Figure 6), the CD160 regions 20–45 (β2 and β3 
strands) and 82–100 (β6-strand and the loop between β6 
and β7 strands) were found to have the highest number 
of contacts in the interface formation of HVEM–CD160 
binding. 
Later, all-atom simulation was performed, which 
revealed that CD160–HVEM complex is very stable as 
RMSD do not increase significantly (Supplementary 
Figure 9). The structure of the complex was stabilized 
after less than 1 ns of MD simulation. In order to find 
which fragments of both proteins are the most flexible, we 
have measured the backbone fluctuations along the MD 
trajectory. The highest fluctuations appear in the loops 
and terminal fragments (see Supplementary Figure 10). 
The lowest fluctuations could be observed for the binding 
fragments in both proteins. These results show that the 
interacting fragments are well matched. The slight increase 
in RMSD results from UNRES inaccuracies in structural 
details; however, the same residues as in the case of 
coarse-grained force field are involved. Nevertheless, the 
structure of the UNRES-predicted complex is similar to 
obtained after MD in AMBER (RMSD αC = 3.38 Å). 
The amino acid residues 20, 22, 30, 32, 43, 44, 
45, 81, 89, and 99 of the CD160 protein are involved in 
the binding site formation. These residues stabilize the 
structure of the complex by forming stable salt bridges 
(Glu27 of HVEM (violet) and Arg89 of CD160 (pink), 
Arg75 of HVEM (violet) and Glu45 of CD160 (pink); 
Figure 7B and 7C, respectively) and hydrophobic 
interactions (see Supplementary Table 2) during MD 
trajectory. The contribution of salt bridges and hydrophobic 
interactions between CD160 and HVEM proteins play 
a very important role in the complex stabilization of 
investigated proteins. Also, very important interactions 
were observed for Glu45CD160, Phe30CD160, and Val32CD160 
amino acids, which are engaged in the interaction with the 
key Tyr23HVEM [21] amino acid residue (Figure 7A). 
DISCUSSION
CD160 inhibits TCR-mediated signaling through 
interaction with HVEM [13], leading to the decrease 
of cytokine production and proliferation by T cells 
[29]. Moreover, CD160 may be implicated in immune 
regulation in different types of disease, such as chronic 
viral infections (HIV, HCV) [35, 36], autoimmune diseases 
(e.g., psoriasis) [37], and cancers [27, 38]. The current 
knowledge suggests that CD160 may be an interesting 
target for therapeutic modulation of immune responses.
In this study, using in vitro experiments and in silico 
modeling, we determined the binding sites of CD160 
that are responsible for the interaction with HVEM, and 
we propose a theoretical structure of CD160 and the 
CD160–HVEM complex.
Figure 4: (A) 3D-structure of UNRES model of the CD160 protein; (B) Schematic topology of the CD160 protein.
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The 3D structure of the CD160 protein is very 
similar to the other protein interactions with HVEM such 
as BTLA and also to other Ig superfamily proteins. It 
is composed of two flat β-sheets, which are formed by 
strands β1, β4, β5, and β9 in one sheet and strands β2, β3, 
β6, β7, and β8 in the other (Figure 4A). So far, the crystal 
structures of the CD160 and the CD160–HVEM complex 
were not determined. 
We aimed at finding the fragment of the 
CD160 protein targeting HVEM by using different 
physicochemical methods like HDX-MS, affinity test, 
and ELISA test. Each of these methods has their own 
limitations. In HDX-MS studies the protein–protein 
complex is created in the solution and the experiment 
is performed in native conditions, but this method can 
provide information about binding sites in protein–protein 
complexes only when the interaction results in allosteric 
changes in the surrounding structure and dynamics of 
proteins [39]. In affinity and ELISA tests, the protein (or 
peptide) is immobilized on solid phase (microcolumn or 
plate), which can influence the conformation of molecules 
[40]. Moreover, ELISA and affinity tests may give false-
positive results due to nonspecific binding of peptides, 
proteins, or antibodies to the surface of microplates [41] 
or to the microcolumns. Therefore, it is reasonable to use 
more than one method to explore the protein interactions. 
In HDX-MS studies, we analyzed the differences 
in deuteration level for the free CD160 and the CD160–
HVEM complex. CD160 (16–21), CD160 (30–34) and 
CD160 (76–87) fragments are the shortest region for 
which significant changes were observed. This suggests 
that the binding sites in CD160 protein are discontinuous 
(formed by different fragments of CD160 sequence) and 
that CD160 interacts with HVEM via short (5–12 aa) 
fragments.
Next, the results from affinity and ELISA tests 
were found to be similar. Peptides which were observed 
in the elution fraction in affinity tests also bound to 
Figure 5: The HVEM (orange)–CD160 (light blue) complex obtained from the UNRES simulation. The interacting 
fragments are colored in red and dark blue.
Figure 6: The contact map scoring obtained for CD160 and HVEM interface from coarse-grained simulations for all 
structures from the most probable cluster. The gray scale (i.e., contact score) indicates the highest probability of contact for black 
and the smallest for white color.
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the HVEM protein in ELISA tests. The strongest 
interaction with HVEM (similar as the whole CD160 
protein) was observed for the longest peptide CD160 
(13–32), which contains the short fragment CD160 
(16–21) that showed difference in the deuteration 
level between free and bound protein in the HDX-MS 
experiment. Additionally, the UNRES-derived structure 
of CD160–HVEM complex showed that Val20CD160 and 
His22CD160 are important for the protein interactions. 
All our data indicate that CD160 (13–32) fragment of 
the CD160 protein is important for the CD160–HVEM 
complex formation. We also identified that the peptide 
CD160 (25–44) also interacts with HVEM protein. 
This peptide contains the fragment CD160 (30–34), 
which was identified as a potential binding site of HVEM 
in HDX-MS experiment. These interactions seem to be 
important for the formation/stability of the CD160–
HVEM complex structure. The Phe30CD160 and Val32CD160 
amino acids are engaged in the interaction with key 
Tyr23HVEM residue. Tyr23HVEM residue was described as 
an important factor for the binding of BTLA [21] or gD 
[21, 25]. In our model of the CD160–HVEM structure, 
we could observe the interactions between Glu45CD160 and 
Tyr23HVEM. Unfortunately, the data obtained from ELISA 
and HDX-MS experiments do not indicate that Glu45CD160 
is important for the complex stabilization. 
The other two interacting fragments CD160 (61–80) 
and CD160 (73–92) are also very suitable for the HDX-MS 
experiment. The most important changes in deuteration 
level were observed for the amino acid sequences 70–75 
and 76–87, which are the part of either CD160 (61–80) or 
CD160 (73–92), or both analyzed peptides. The presented 
model of HVEM–CD160 protein complex does not show 
the interactions between the fragment 70–75 of CD160 
and HVEM protein, but suggest that the amino acids from 
83 to 100 are important for the complex formation, in 
particular Arg89CD160 and Leu97CD160. Unfortunately, in our 
HDX-MS analysis (as a result of pepsin digestion) only 
one peptide (CD160 (88–101)) was detected and for which 
the small changes in deuteration level were observed. The 
affinity test showed that the CD160 (85–104) peptide 
interacts with HVEM protein, but results from ELISA 
test indicated that CD160 (85–104) interacts with plates 
in a nonspecific manner. For that reason the role of that 
fragment in CD160–HVEM interactions is not clear. 
The HVEM engages in the BTLA–HVEM 
interaction with similar surfaces as in our predicted 
CD160–HVEM complex. In our model, the whole 
Figure 7: (A) The HVEM key residue Tyr23 interacting with Val32 and Glu45 of the CD160 protein. The colors in this drawing are the 
same as in Figure 5; (B) The visualization of salt bridge between Glu27 of HVEM (violet) and Arg89 of CD160 (pink) (C) The visualization 
of salt bridge between Arg75 of HVEM (violet) and Glu45 of CD160 (pink).
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fragment 17–42HVEM is involved in interactions with 
the CD160 protein. In the all-atom CD160–HVEM 
complex, after MD simulation, the fragment involved 
in the interaction is observed to be shorter: 17–39HVEM. 
This binding fragment in CD160–HVEM complex is 
almost identical to the most significant BTLA–HVEM 
binding fragment 14–39HVEM [21]. The Tyr23HVEM residue 
plays a crucial role in the BTLA–HVEM [21] interface 
and in the CD160–HVEM complex, according to our 
predictions. It indicates that the molecular recognition 
between HVEM (red) and BTLA (green) or HVEM and 
CD160 (blue) might be very similar (Figure 8). Although 
the binding site of the CD160 or BTLA proteins to the 
HVEM is very similar, in the 3D model (see Figure 8) 
it can be seen that the CD160 and BTLA proteins are 
displaced from each other as they are structurally different. 
The BTLA protein forms a very compact structure and 
more stable complex with the HVEM protein. This is 
confirmed by our nano differential scanning fluorimetry 
(nanoDSF) studies, through which we analyzed the 
thermal stability of both proteins (CD160 and BTLA) and 
both complexes (CD160–HVEM and BTLA–HVEM). 
The results obtained by us (unpublished data) indicate 
that the CD160 protein is less stable in comparison with 
BTLA and HVEM proteins. In addition, the CD160–
HVEM complex is also found to be less stable than the 
BTLA–HVEM. The results of our experiments, in which 
we determined the binding sites between the CD160 
and HVEM are in good agreement with the theoretical 
results, in which we obtained the structure of the CD160–
HVEM complex without the experimental data. This high 
agreement between experimental and theoretical results 
indicate that the structure of the CD160–HVEM complex 
we proposed is robust. Our results can be useful in 
future to evaluate various possible strategies to block the 
HVEM protein in the CD160–HVEM or BTLA–HVEM 
interactions. However, additional studies are needed to 
better understand CD160–HVEM interactions.
MATERIALS AND METHODS
Sources of CD160 and HVEM proteins
The recombinant human CD160 protein 
was purchased from Novoprotein, USA (#CA35). 
Recombinant human protein HVEM with His Tag was 
purchased from Sino Biological Inc., China (#10334-
H08H). Human HVEM-Fc protein was purchased from 
ACROBiosystems, USA (#HVM-H5258). For ELISA, 
CD160 protein was biotinylated using the EZ-link NHS-
PEG4-Biotin (Thermo Fisher Scientific), according 
to the manufacturer’s instruction. CD160 protein was 
deglycosylated using PNGase F enzyme (Promega) 
according to the manufacturer’s instruction.
Peptide synthesis and purification
The peptides were synthesized using standard 
protocols for the solid phase peptide synthesis [42]. 
The crude peptides were purified by RP-HPLC using a 
semipreparative Luna C8(2) column (20 × 250 mm, 5 µm) 
and 0.1% TFA in H2O (as solvent A) and 80% acetonitrile 
in water containing 0.08% TFA (as solvent B). For all 
peptides, a linear gradient from 20% B to 60% B in 
140 mins was used; the flow rate was adjusted to 15 ml/
min and the separation was monitored by UV absorbance 
Figure 8: Comparison between the theoretical structure of the CD160 (blue)–HVEM (red) complex (UNRES model) 
with the crystal structure of BTLA (green)–HVEM (red) complex (PDB code:2AW2).
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at 222 nm. The purity of peptides was analyzed in linear 
gradient from 5 to 100% B in 60 min by using LCMS ESI/
IT-TOF (Shimadzu).
Preparation of microcolumn and affinity tests
The immobilization of HVEM protein in a 
microcolumn and affinity tests were performed as 
described previously [43].
Enzyme-linked immunosorbent assay (ELISA)
ELISA tests were performed on a 96-well clear 
Nunc Immobilizer Streptavidin microplate (Thermo 
Scientific). In the first step, the plate was washed 5 times 
(200 µl/well) with PBS-T (5 mM Na2HPO4, 150 mM NaCl 
with addition of 0.3 M NaCl and 0.05% Tween-20, pH 
7.4) and then coated with 100 µl of biotinylated peptides 
(1 µg/ml) in PBS-T for 1 hour at 25° C. Biotinylated 
CD160 protein (1 µg/ml) and PBS-T were used as positive 
and negative control, respectively. After washing with 
PBS-T, non-coated sites were blocked using the blocking 
solution (200 µl/well; Candor) for 2 h at 25° C. Then, after 
washing, 100 µl HVEM-Fc at different concentrations 
per well were added and incubated for 1 hour at 25° C. 
Goat antihuman IgG(H+L)–HRP (Bio-Rad) antibody 
(1:3000, 100 µl/well) was then added and incubated for 
1 hour at 25° C. Finally, the binding of HVEM-Fc with 
peptides were determined by the addition of 100 µl/well of 
3,3′,5,5′-tetramethylbenzidine (TMB, Thermo Scientific). 
Absorbance was measured using Infinite M200 Pro of 
Tecan at 650 nm and 492 nm. Statistical analysis of the 
results was performed using the one-way analysis of 
variance (GraphPad Prism 7).
Hydrogen/deuterium exchange experiments
The method was performed as described before, 
with small modifications [44]. In the first step of the 
analysis, the list of CD160 peptides was created using 
a nondeuterated protein sample. Fifteen microliters 
portions of the CD160 protein stock solution (105 μM) 
were diluted by adding to 35 μl of PBS (5 mM Na2HPO4, 
150 mM NaCl, pH 7.4). The sample was acidified by 
the addition of 10 μl H2O stop buffer (150 mM NaCl, 6 
M guanidine hydrochloride, 1 M tris(2-carboxyethyl)
phosphine (TCEP), 2 M glycine, pH 2.4). The sample 
was first digested offline for 1 min with 5 μl of protease 
type XIII from Aspergillus saitoi (48 μM, in 1% formic 
acid). Then, sample was digested online for 1.5 min 
using a 2.1 mm × 30 mm immobilized pepsin resin 
column (Poroszyme, ABI, Foster City, CA) with 0.07% 
formic acid in water as mobile phase (200 μl/min flow 
rate) kept at 13° C. Peptides were loaded onto the 2.1 
mm × 5 mm C18 trapping column (ACQUITY BEH C18 
VanGuard precolumn, 1.7 μm resin, Waters, Milford, 
MA). Trapped peptides were eluted onto a reversed phase 
C18 column (Acquity UPLC BEH, 1.0 × 100 mm, 1.7 μm 
resin, Waters, Milford, MA) using a 7–35% gradient of 
acetonitrile in 0.1% formic acid at 55 μl/min flow rate 
controlled by the nanoACQUITY binary solvent manager. 
Single run time was 13.5 min. Temperature of all fluidics, 
columns, and valves, with the exception of the pepsin 
digestion column kept at 13° C, was maintained at 0.5° C 
using the HDX Manager (Waters, Milford, MA). Outlet 
of the C18 column was directly coupled to the ion source 
of SYNAPT GS HDMS mass spectrometer (Waters, 
Milford, MA). Leucine-enkephalin (Sigma) was used for 
carrying out lock mass and activation. Mass spectra were 
acquired in MSE mode over the m/z range of 50–2000. The 
spectrometer parameters were set as follows: ESI positive 
mode, capillary voltage 3 kV, sampling cone voltage 
35 V, extraction cone voltage 3 V, source temperature 
80° C, desolvation temperature 175° C, and desolvation 
gas flow 800 L/h. The spectrometer was calibrated using 
standard calibrating procedures. Peptides identification 
was performed with ProteinLynx Global Server software 
(PLGS, Waters, Milford, MA). We used a randomized 
database. The list of peptides, with peptide m/z, charge, 
retention time, and ion mobility/drift time was passed to 
the DynamX 3.0 HDX-MS data analysis software (Waters, 
Milford, MA).
Complex formation was initiated by mixing 84 µl of 
CD160 (c=105 µM) with 56 µl of protein HVEM (c=157 
µM), 1:1 ratio in PBS. The mixture was incubated for 
2 h at 25° C to enable the complex formation. Hydrogen/
deuterium (H/D) exchange experiments were performed 
similarly as described for the nondeuterated sample. 
The reaction buffer was prepared using D2O (99.8% 
Cambridge Isotope Laboratories, Inc.), and pH was 
adjusted using DCl (Sigma) to 2.4 for stop buffer. 
5 μl of protein stock was mixed with 45 μl D2O reaction 
buffer and the exchange reactions were performed for 
different time periods (10 s, 1 min, 5 min, 25 min, and 
2 h) at room temperature. The exchange was quenched by 
reducing the pH to 2.4 by adding the reaction mixture to 
stop buffer cooled on ice (150 mM NaCl, 6 M guanidine 
hydrochloride, 1 M TCEP, 2 M glycine, pH 2.4). After 
quenching in the stop buffer, the sample was digested 
offline with Aspergillus saitoi protease XIII and the 
sample was manually injected into the nanoACQUITY 
(Waters, Milford, MA) UPLC system. Afterward, online 
pepsin digestion and liquid chromatography (LC) and 
MS analysis were conducted the same as described for 
nondeuterated samples.
Two control experiments were performed to 
exclude exchange artifacts. To assess the minimal level 
of exchange (in-exchange), 45 µl of D2O reaction buffer 
and 10 µl of stop buffer were mixed and cooled on ice, 
prior to the addition of 5 µl protein CD160 stock sample. 
Sample was immediately digested offline and online 
and subjected to LC/MS analysis, as the H/D exchange 
samples described above. Deuteration level measured for 
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in-exchange control was calculated and denoted as 0% 
exchange (Mex
0). To assess the maximal level of exchange 
(out-exchange), the deuteration reaction was performed 
for 24 h, and subsequently quenched and processed as 
described above. Deuteration level measured for out-
exchange control was calculated and denoted as 100% 
exchange (Mex
100). Each H/D exchange experiment was 
repeated four times, the presented results are the mean of 
these replicates.
H/D exchange data analysis
The analysis was performed as described before 
[44]. The deuteration levels of each peptide were 
calculated automatically using DynamX 3.0 software. 
The peptide list was obtained from undeuterated samples 
using the PLGS program. The list was further filtered in 
the DynamX 3.0 program, using the following criteria: 
minimum intensity - 3000; minimum products per 
amino acid - 0,3; minimum score - 7,0; maximum MH+ 
error (ppm) - 10. All results from exchange and control 
experiments obtained from the automated analysis 
were subsequently verified manually. Overlapping or 
ambiguous isotopic envelopes were discarded.
The percentage of relative deuterium uptake 
(% Deuteration) of every peptide was calculated following 
the formula, where (Mex
0 )  and (Mex
100 )  indicate the 
minimum and maximum exchange values obtained in 
control experiments described before [44], respectively.
% Deuteration=
(Mex -Mex
0 )
(Mex
100 -Mex
0 )
×100
Final kinetic results, error bars, the values of the 
difference in exchange, and figures were calculated and 
plotted using the in-house scripts written in R language 
[45]. Error bars for fraction exchanged represent standard 
deviations calculated from at least three independent 
experiments. The difference in the Fraction Exchanged 
(Δ Fraction Exchanged) was calculated by subtracting the 
values for peptides in the complex from the values for the 
same peptides in the apo-state, with the error bars being 
calculated as the square root of the sum of the variances 
from compared states. P-values were calculated using 
Student’s t-test for peptides after n time of HD exchange. 
Student’s t-test for two independent samples with unequal 
variances and sample sizes (known as Welsh t-test) was 
carried out to evaluate differences between the same 
peptides in two different states, as described before [46].
Model building of the CD160 protein
The structure of the CD160 protein was obtained 
initially by homology modeling and then was calculated 
in a coarse-grained force field. First, structural models 
were obtained with the use of I-TASSER server [47–50]. 
I-TASSER homology modeling was based on templates 
of the highest significance in the threading alignments, 
and the ten best templates were used to build the CD160 
models. There were no homologous template structures 
for the C-terminal part of the protein (119–159 fragments). 
This part of the structure was therefore obtained in the next 
step by using the multiplexed replica exchange molecular 
dynamics (see next indention). For each target, I-TASSER 
simulations generate a large ensemble of conformation, 
which were divided into clusters based on their structural 
similarity. The final five structures were average structures 
corresponding to the five largest structure clusters. For 
those structures, a C-score, the confidence score for 
estimating the quality of predicted models by I-TASSER, 
were calculated. The C-score is typically in the range of 
–5 and 2 [50, 51], where a higher C-score value a higher 
confidence in a model. The CD160 model with the highest 
C-score was selected for the structure calculation in a 
coarse-grained force field. 
To get folded structures of the full length CD160 
protein, the I-TASSER model in the multiplexed replica 
exchange molecular dynamics trajectories (MREMD) 
[51, 52] with the coarse-grained UNRES (from UNited 
RESidue) [53, 54] force field were calculated. The 
simulations were performed with the use of the dynamic 
fragment assembly (DFA) technique, in which knowledge-
based information corresponding to secondary structure, 
inter-residue-contacts, and local structure is incorporated 
into a target function as additional energy terms [55, 56]. 
Subsequently, the weighted-histogram analysis method 
(WHAM) was applied to calculate the relative free 
energy of each structure of the last part of the MREMD 
simulation [57, 58] and then cluster analysis was used to 
obtain clusters with the lowest free energies. Finally, the 
average structure from each cluster was converted to an 
all-atom model and refined by using restrained molecular 
dynamics simulations with the AMBER14 all-atom force 
field (3.7 ns). Final conformations were picked based on 
the following criteria:
(i) protons in the CD160 protein, exchanged on 
deuterium in HDX-MS experiment are situated in the 
unstructured fragments of the protein and in the solvent-
exposed part of the protein. This was the key information 
during the selection of the theoretically appointed structure 
of the CD160 protein,
(ii) the fragments binding to HVEM, 
indicated by HDX-MS technique, should be in close 
contact and should be located in the solvent-exposed areas,
(iii)  correct positions of disulfide bonds in 
CD160 protein model,
(iv) proper topology of CD160 model in a IgV 
immunoglobulin fold.
The best 3D model of CD160 protein among all 
calculated structures was validated using the following 
programs PROCHECK [59], VERIFY3D [60], and 
ProSA-Web (Protein Structure Analysis) [61]. For 
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the analysis details see description in Supplementary 
Materials (see Supplementary Figure 6). 
CD160–HVEM complex formation by molecular 
docking 
The best 3D model of CD160 protein was used 
for protein docking with HVEM protein by using 
coarse-grained UNRES force field [62, 63] with newly 
developed restrains on tertiary structures of monomers 
[64]. The experimental data was not used during the 
docking procedure. HVEM coordinates were used from 
the structure of the BTLA-HVEM complex (PDB code: 
2AW2). As a starting structure a randomly oriented 
proteins were used and multiplex replica exchange 
molecular dynamics trajectories were calculated 
(MREMD) [52]. After simulation, the weighted histogram 
analysis and clustering of the obtained structures was 
performed. For the dominant cluster (with lowest free 
energy) contact map analysis was performed [65]. In the 
calculations the cuttoff1 was set to 8 and the cutoff2 was 
set to 10. The most probable cluster was converted to 
all-atom structure with use of PULCHRA [66] software. 
Afterward, to refine structures which were derived 
from coarse-grained models and check the stability of 
the complex, the all-atom molecular dynamics (MD) 
simulation in AMBER ff14SB force field was performed 
[67]. Simulations were performed in explicit solvent 
(TIP3PBOX water model) in water box and in standard 
temperature (298K). Size of the water box was set as 15Å 
of water molecules in each side of the protein. Interactions 
in the CD160–HVEM protein were analyzed by using 
YASARA program [68]. 
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